Clinical trial
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
NCT00063713 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00063713 |
|---|---|
| Title | VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma |
| Official title | A Phase 2 Study of VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mantle Cell Lymphoma |
| Intervention type | Drug |
| Interventions | VELCADE TM (bortezomib) for Injection |
| Enrollment | 152 |
| Start date | Jun 1, 2003 |
| Primary completion | Dec 1, 2005 |
| First posted | Jul 4, 2003 |
| Last update posted | Feb 11, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: